| Literature DB >> 35898275 |
Chen-Han Zhang1, Yi-Peng Ge1, Yong-Liang Zhong1, Hai-Ou Hu1, Zhi-Yu Qiao1, Cheng-Nan Li1, Jun-Ming Zhu1.
Abstract
Background: Massive bleeding throughout aortic repair in acute type A aortic dissection (ATAAD) patients is a common but severe condition that can cause multiple serious clinical problems. Here, we report our findings regarding risk factors, short-term outcomes, and predicting model for massive bleeding in ATAAD patients who underwent emergent aortic repair.Entities:
Keywords: aortic (rupture) dissection; bleeding; clinical research; perioperative management; surgery strategy
Year: 2022 PMID: 35898275 PMCID: PMC9309227 DOI: 10.3389/fcvm.2022.892696
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X
FIGURE 1Bleeding classification according to the UDPB.
Preoperative characteristics of the study population.
| Variables | Massive bleeding group ( | Non-massive bleeding group ( | |
| Male sex | 59 (86.8%) | 234 (70.3%) | 0.005 |
| Age (years) | 52.13 ± 11.96 | 48.73 ± 11.63 | 0.029 |
| Body mass index | 24.99 ± 3.99 | 26.72 ± 7.86 | 0.010 |
| Hypertension | 57 (82.6%) | 277 (83.2%) | 0.269 |
| Diabetes mellitus | 1 (1.4%) | 12 (3.6%) | 0.365 |
| Past cerebral infarction | 1 (1.4%) | 9 (2.7%) | 0.553 |
| Preoperative anticoagulant | 5 (7.4%) | 13 (3.9%) | 0.211 |
| Acute cardiac tamponade | 1 (1.4%) | 6 (1.8%) | 0.839 |
| Acute myocardial infarction | 1 (1.4%) | 6 (1.8%) | 0.839 |
| Renal failure | 1 (1.4%) | 5 (1.5%) | 0.974 |
| Malperfusion syndrome | 6 (8.7%) | 31 (9.3%) | 0.872 |
| White blood cell count (×109/L) | 12.11 ± 4.36 | 11.65 ± 4.12 | 0.404 |
| Red blood cell count (×109/L) | 4.38 ± 0.55 | 4.40 ± 0.74 | 0.815 |
| Platelet count (×109/L) | 180.72 ± 53.28 | 198.26 ± 75.57 | 0.024 |
| Mean platelet volume (fL) | 10.56 ± 0.90 | 10.51 ± 1.14 | 0.053 |
| Hemoglobin (g/L) | 129.34 ± 22.26 | 134.78 ± 18.41 | 0.036 |
| Prothrombin time (s) | 13.62 ± 4.91 | 12.91 ± 3.16 | 0.713 |
| International normalized ratio | 1.13 (1.04, 1.17) | 1.11 (1.04, 1.77) | 0.673 |
| D-dimer (ng/mL) | 3036.5 (1630, 11970.5) | 2040 (790.5, 3229.5) | 0.007 |
| Fibrin degradation products (μg/mL) | 46.76 (14.68, 95.11) | 18.76 (7.33, 37.56) | 0.001 |
| Aspartate transaminase level (U/L) | 22 (17, 29.5) | 23 (17, 35) | 0.355 |
| Alanine transaminase level (U/L) | 20 (14, 28.5) | 22 (15, 38) | 0.067 |
| γ-GT (U/L) | 24 (14, 35.5) | 31 (19, 65.75) | 0.058 |
| Serum creatinine (μmol/L) | 88.2 (69.72, 129) | 84.3 (68.32, 106.22) | 0.251 |
| Blood urea nitrogen (mg/dL) | 7.83 ± 3.25 | 7.19 ± 4.39 | 0.268 |
| Serum lipase (U/L) | 12.1 (7.75, 24.1) | 12.6 (8.2, 20.65) | 0.853 |
| Serum amylase (U/L) | 44.45 (36.92, 65.25) | 46.1 (35.3, 59.5) | 0.735 |
| CK-MB (ng/mL) | 1.65 (1.1, 6.67) | 1.3 (0.8, 2.97) | 0.01 |
| Cardiac troponin I (ng/mL) | 0.01 (0, 0.15) | 0.01 (0, 0.06) | 0.464 |
| Myoglobin (ng/mL) | 40.25 (25.72, 96.32) | 29.5 (19.82, 49.4) | 0.004 |
Values are expressed as number (%), median (lower quartile, upper quartile), or mean ± SD.
Surgical data of study population.
| Variables | Massive bleeding group ( | Non-massive bleeding group ( | |
| Emergent surgery | 58 (84.1%) | 240 (80.8%) | 0.044 |
| Aortic root replacement | 32 (46.4%) | 140 (42.0%) | 0.590 |
| Hemiarch replacement | 2 (2.9%) | 58 (17.4%) | 0.002 |
| Total arch replacement | 62 (89.9%) | 253 (76.0%) | 0.012 |
| Concomitant CABG | 6 (8.7%) | 25 (7.5%) | 0.736 |
| Concomitant vascular bypass | 4 (5.8%) | 18 (5.4%) | 0.896 |
| Concomitant aortic valvuloplasty | 1 (1.4%) | 10 (3.0%) | 0.472 |
| Concomitant mitral valve replacement | 1 (1.4%) | 1 (0.3%) | 0.217 |
| Concomitant abdominal aortic replacement | 1 (1.4%) | 0 (0) | 0.028 |
| Cardiopulmonary bypass time (min) | 209.60 ± 43.55 | 187.83 ± 42.09 | <0.001 |
| Aortic cross-clamp time (min) | 118.09 ± 26.97 | 108.44 ± 28.25 | 0.01 |
| Circulatory arrest time (min) | 23.59 ± 11.35 | 22.94 ± 12.25 | 0.651 |
Values are expressed as number (%) or mean ± SD. CABG, coronary artery bypass graft surgery.
Risk factors of postoperative massive bleeding.
| Variables | OR | 95% CI | |
| Male sex | 6.493 | 0.001 | 2.429–17.360 |
| Elder patients | 1.029 | 0.05 | 1.000–1.059 |
| BMI | 0.879 | 0.003 | 0.806–0.957 |
| Emergent surgery | 3.112 | 0.016 | 1.235–7.843 |
| Prolonged cardiopulmonary bypass time | 1.012 | 0.002 | 1.004–1.021 |
| Hemoglobin levels | 0.976 | 0.002 | 0.959–0.993 |
| D-dimer levels | 1.000 | 0.037 | 1.000–1.002 |
| Fibrin degradation products levels | 1.019 | 0.008 | 1.005–1.033 |
| Hemiarch replacement | 5.045 | 0.037 | 1.098–23.173 |
| Total arch replacement | 14.405 | 0.004 | 2.046–101.404 |
FIGURE 2Survival in patients with and without massive bleeding.
Short-term outcomes of study population.
| Variables | Massive bleeding group ( | Non-massive bleeding group ( | |
| Mortality | 11 (15.9%) | 13 (3.9%) | 0.001 |
| Respiratory failure | 28 (41.2%) | 70 (21.0%) | 0.001 |
| Acute kidney injury | 18 (26.5%) | 32 (9.6%) | 0.001 |
| Endotracheal intubation time (h) | 41 (17.75, 96) | 16 (12, 36) | 0.001 |
| ICU stay (days) | 4 (2, 8) | 2 (1, 4) | 0.001 |
| Cerebrovascular event | 7 (10.3%) | 30 (9.0%) | 0.739 |
| Paraplegia | 4 (5.9%) | 15 (4.5%) | 0.626 |
| Reintubation | 9 (13.2%) | 31 (9.3%) | 0.325 |
| Re-exploration for bleeding | 19 (27.5%) | 0 (0) | 0.001 |
Values are expressed as number (%), median (lower quartile, upper quartile), or mean ± SD.
FIGURE 3ROC curve of the model for predicting massive bleeding.
FIGURE 4Calibration plot of the model for predicting massive bleeding.